A rare case has been registered in the Netherlands, where a 72-year-old man died after a full 613 days of being infected with the coronavirus, becoming the patient with the longest infection in history.
He was infected in February 2022 while he had a very weak immunity, because he was also taking drugs to reduce immunity (immunosuppressant) as he suffered from a type of blood cancer and some other diseases.
His situation was actually complicated by the development after the transplant of another tumor, a diffuse large B-cell lymphoma, for which he had been given the anticancer drug rituximab, a drug that eliminates both malignant and normal B cells, thus also those that normally produce antibodies directed against the Sars-Cov-2 coronavirus.
Doctors say that his infection with the coronavirus was so long that the virus managed to mutate 50 times, transforming into other variants.
Although the patient had previously received multiple doses of the Covid vaccine, his compromised immune system left him unable to produce a detectable antibody response against the virus.
Admitted to the Amsterdam University Medical Center, doctors tried to treat his infection with monoclonal antibodies against Sars-Cov-2 and other drugs, but without getting the desired results.
In the case of the 72-year-old, who died in October 2023 from a relapse of his hematological condition after remaining positive for the coronavirus for a total of 613 days (the longest infection ever documented so far), the first signs of viral mutations appeared as early as 21 days after treatment with monoclonal antibodies against the Sars-Cov-2 coronavirus. In more detail, the genome sequence, which initially showed an infection due to Omicron's BA.1.17 variant, showed the development of a mutation known as S:E340K, which gives the virus resistance to sotrovimab, or its monoclonal antibody. which the patient had was treated.
Subsequent analysis revealed that the virus has undergone "over 50 mutations compared to the BA.1 variants that were simultaneously circulating in the world, with multiple amino acid substitutions, including at the level of the ACE-2 receptor binding site in the Spike protein." (S:L452M /K and S:Y453F),” observe the authors of the report.